Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

BUY
$0.33 - $1.39 $93,217 - $392,644
282,478 New
282,478 $358,000
Q4 2022

Feb 14, 2023

SELL
$0.5 - $0.72 $12,115 - $17,446
-24,231 Reduced 38.33%
38,984 $20,000
Q3 2022

Nov 14, 2022

BUY
$0.87 - $1.36 $54,997 - $85,972
63,215 New
63,215 $46,000
Q2 2022

Aug 16, 2022

SELL
$0.86 - $2.06 $54,477 - $130,492
-63,346 Closed
0 $0
Q1 2022

May 17, 2022

BUY
$1.83 - $3.02 $33,930 - $55,993
18,541 Added 41.38%
63,346 $130,000
Q4 2021

Feb 15, 2022

SELL
$2.88 - $4.3 $86,051 - $128,479
-29,879 Reduced 40.01%
44,805 $129,000
Q3 2021

Nov 16, 2021

BUY
$3.72 - $5.35 $182,968 - $263,139
49,185 Added 192.89%
74,684 $316,000
Q2 2021

Aug 16, 2021

SELL
$3.83 - $5.98 $18,889 - $29,493
-4,932 Reduced 16.21%
25,499 $136,000
Q1 2021

May 18, 2021

BUY
$3.33 - $8.76 $101,335 - $266,575
30,431 New
30,431 $142,000
Q3 2020

Nov 17, 2020

SELL
$3.23 - $4.3 $446,208 - $594,023
-138,145 Closed
0 $0
Q2 2020

Aug 17, 2020

BUY
$3.31 - $6.54 $457,259 - $903,468
138,145 New
138,145 $466,000
Q4 2019

Feb 14, 2020

SELL
$5.61 - $8.57 $63,684 - $97,286
-11,352 Closed
0 $0
Q3 2019

Nov 14, 2019

SELL
$7.56 - $15.44 $50,296 - $102,722
-6,653 Reduced 36.95%
11,352 $86,000
Q2 2019

Aug 15, 2019

BUY
$5.4 - $15.5 $97,227 - $279,077
18,005 New
18,005 $244,000
Q1 2019

May 16, 2019

SELL
$3.6 - $6.22 $44,161 - $76,300
-12,267 Closed
0 $0
Q4 2018

Feb 15, 2019

SELL
$2.89 - $7.91 $67,302 - $184,208
-23,288 Reduced 65.5%
12,267 $36,000
Q3 2018

Nov 14, 2018

BUY
$5.59 - $10.45 $61,305 - $114,605
10,967 Added 44.6%
35,555 $290,000
Q2 2018

Aug 15, 2018

BUY
$7.98 - $12.39 $196,212 - $304,645
24,588 New
24,588 $239,000

Others Institutions Holding ZYNE

About Zynerba Pharmaceuticals, Inc.


  • Ticker ZYNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,753,100
  • Description
  • Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for t...
More about ZYNE
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.